better health, better life

1. better health, better life mariposa Health Corporate Presentation February 2016

2. Forward Looking Statements This presentation contains certain statements which may constitute "forward-looking statements.” Such statements are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements. No representation or warranty, express or implied, is made by Mariposa Health that the material contained in this presentation will be achieved or prove to be correct. Except for statutory liability which cannot be excluded, each of Mariposa Health, its officers, employees and advisers expressly disclaims any responsibility for the accuracy or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission there from. Mariposa Health accepts no responsibility to update any person regarding any inaccuracy, omission or change in information in thispresentation or any other information made available to a person nor any obligation to furnish the person with any further information.Investment in Mariposa Health should be considered speculative.

3. Introduction • Our market focus is COPD, the 3rd leading cause of death in the US • 2 products in Phase 2 clinical trials: 1) oral bacterial vaccine, 2) anti-inflammatory/anti-oxidant • Both are complementary to current treatments • Out-licensed for development & marketing in China • Target on-sale or out-license to larger pharma by end 2018

4. Company Information • Mariposa Health Inc was formed merger of Mariposa Health Ltd (Australia) and a US shell • Shareholders: 65 • Shares on issue: 9,881,211 • Warrants exercisable at listing: 438,789 • Fully diluted share structure: 10,320,000 • SEC filings: Forms 10K, 10Q

5. Board & Management

6. Chronic Obstructive Pulmonary Disease (COPD) • 3rd leading cause of death in the United States. • 12.7 million people have been diagnosed with COPD, up to 24 million have the disease without being aware. . • COPD causes serious long-term disability and early death. • At this time there is no cure, and the number of people dying from COPD is growing. Source: American Lung Association, 2016 - http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/how-serious-is-copd.html

7. COPD: We address a major market • Hospital costs: $6billion (US) • Disease costs: $30-40billion annual (US) • Drug sales: $6billion (US) • Major drugs: Spiriva (BII), Advair (GSK) • Our drugs are complementary to existing treatments Source: American Lung Association, 2016 - http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/learn-about-copd/how-serious-is-copd.html

8. Market dynamics • Market leaders coming off patent • Generics bring low pricing • Introduction of numerous similar (bronchodilator + steroid) • Gaps in existing treatment: Much room to reduce “Medical interventions” • Aim: Unique benefits, Higher prices & Large market

9. COPD: A complex disease Cigarette SmokeBiomass particles and particulates Host factors, exogenous oxidative stress and amplifying mechanisms Recurring bacterial infections Faulty immune activity LungInflammation Oxidative Stress Proteases RepairMechanisms COPDPathology From Global Guideline for COPD : GOLD

10. Two drugs: Place in treatment Cigarette SmokeBiomass particles and particulates Host factors, exogenous oxidative stress and amplifying mechanisms Faulty immune activity TA-270: Anti-inflammatory LungInflammation HI-164: Bacterial vaccine TA-270: Anti-oxidant Oxidative Stress Proteases RepairMechanisms COPDPathology From Global Guideline for COPD : GOLD TA-270: Inhibits 5-lipoxygenase and peroxynitrite HI-164: Non-typeable H. influenzae

11. HI-164 Oral, mucosal vaccine to Non-typeable H. influenza One Phase 1 study Two Phase 2 studies of 6 & 9 months duration 21 hospital centers

12. HI-164-OV: Reduction in exacerbations of COPD Phase 2 studies in COPD patients (post-hoc analysis: Studies H-002/4, HI-005) Placebo (existing treatment) HI-164OV Study designs COPD patients, m or f Randomised, db, pc HI002/4, n=140; HI-005, n= 90 Treatment with oral HI-164 tablets or placebo once daily for 3 days, repeated after 4 & 8 weeks Duration of study: HI002/4 6 months; HI-005 9 months Exacerbations (n) p = 0.0009 p = 0.002 p = 0.01 Patients <65 years All ages All p-values: Statistical differences, active vs placebo (N= HI-002/004, A 68, P 72; HI-005, A 34, P 56) Definition of a moderate to severe exacerbation includes: + Patient is admitted to hospital or prescribed corticosteroid or antibiotic to treat the exacerbation ++ Patient is admitted to hospital or prescribed corticosteroid to treat the exacerbation

13. Increased time to first episode of COPD (Post hoc analysis, Patients aged <65years, Study HI-005; n= a34, p56) 1.00 Log-rank test, p<0.01 p = 0.02 HI-164OV Placebo 0.75 Survival distribution 0.50 0.25 0.0 250 350 50 150 Days to first exacerbation

14. HI-164OV: Effects on hospital admissions (Post hoc analysis, Patients aged <65years, Study HI-005) Reduction in exacerbations and hospital admissions was also observed in Study HI-002/004

15. Next trial • Phase 2 clinical trial under IND • Study in patients aged 65 years or less with COPD (chronic bronchitis)

16. TA-270 Oral, inhibitor of 5-lipoxygenase (5-LO) and peroxynitrite(ONOO-) Five Phase 1 studies Four Phase 2 studies of 1-4 weeks duration Studies in Japan, EU and UK Improve chronic lung capacity Improve lung epithelium, oxygenation of RBC

17. Inhibition of 5-LO (%) Concentration (mol/L) 1.00E-09 1.0E-08 1.00E-09 N-Acetylcysteine TA-270 Tyrosine Zileuton 1.0E-07 1.00E-08 1.00E-08 1.0E-06 1.00E-07 1.00E-07 1.0E-05 1.00E-06 1.00E-06 1.0E-04 1.00E-05 1.00E-05 Inhibition of LTB4 (%) TA-270: Dual Mode of Action, More Potent Effects 1. Superior free radical scavenging 2. Superior Inhibition of leukotriene pathway Inhibition of peroxynitrite (%) 100 80 60 40 20 0 -20 TA-270 TA-270 TA-270 - Superior free-radical scavenging to N’acetylcysteine - More potent 5-LO and LTB4 inhibition than Zileuton

18. TA-270: Complementary improvements in breathing (Exploratory Phase 2; Moderate to severe COPD) Current medications Increase in FEV1 from Baseline (mL) • Patients in Study TA-007 may have been taking Spiriva, Advair or a similar product • Study TA-007, Open label Phase 2, n=13 Source: TA-270 data on file, FDA approved information, publications; TA-270 shows change vs Baseline, others change vs. placebo

19. Path forward • Reformulation of oral form: patent life to 2036 • Preliminary, inhaled dose form

20. Path to Value II

21. License agreement for HI-164 in China • Shanxi Kangbao Biological Products Company • Conditions: • Exclusive license for the territories • Up-front payment, milestones & royalties (all non-dilutionary) • Chinese partner pays full cost of development in the territories • .

22. Patent Families

23. Budget • Funds two projects to be in a high value saleable form, including: • IND preparations • Clinical trials • Patent and brand build

24. Share ownership

25. License agreement for HI-164 in China • Shanxi Kangbao Biological Products Company • Conditions: • Exclusive license for the territories • Up-front payment, milestones & royalties (all non-dilutionary) • Chinese partner pays full cost of development in the territories • .

26. High Return Potential • Out-license provides non-dilutive access to an emerging market • Corporate filings are in an advanced stage to listing • An investment is an opportunity for significant growth while addressing a significant need

27. better health, better life mariposa Health For More Information Please Contact: Philip Comans, CEO Email: pcomans@mariposahealth.com.au